摘要
目的 对大肠息肉患者肠道菌群的结构特征进行初步分析，了解大肠息肉患者肠道菌群特征。方法收集2022年09月至2023年12月就诊于大理大学第二附属医院符合纳排标准大肠息肉患者及同期健康体检者的粪便样本，通过16SrDNA基因测序法对肠道菌群测序数据进行分析。结果 与健康对照组相比，初发性肠息肉和复发性肠息肉的肠道菌群多样性及丰度均下降。在门水平，初发组和复发组的变形菌门相对丰度升高，拟杆菌门相对丰度降低；在属水平，初发组和复发组患者肠道大肠杆菌-志贺菌属、链球菌属和瘤胃球菌属相对丰度升高，普拉梭菌属和琼脂杆菌属相对丰度降低。复发组中肠球菌、链球菌、放线菌、罗姆布茨菌和Parasutterella菌为优势菌群。结论 复发性肠息肉患者肠道菌群多样性及丰度显著减少，肠球菌属、放线菌属和罗姆布茨菌属为优势菌群，这对预防大肠息肉复发具有重要意义。
关键词： 大肠息肉；肠道菌群；16SrDNA测序法；复发性肠息肉；拟杆菌门
Abstract
Objective To analyze the structural characteristics of intestinal flora in patients with colorectal polyps, and to understand the characteristics of intestinal flora in patients with colorectal polyps. Methods Stool samples of patients with large intestine polyps meeting the ataxic standard and healthy physical examination subjects were collected from September 2022 to December 2023 in the Second Affiliated Hospital of Dali University, and the intestinal flora sequencing data were analyzed by 16SrDNA gene sequencing method. Results Compared with the healthy control group, the diversity and abundance of intestinal flora decreased in both primary and recurrent intestinal polyps. At the phylum level, the relative abundance of Proteobacteria increased in the initial and recurrent groups, while the relative abundance of Bacteroidetes decreased. At the genus level, the relative abundences of Escherichia coli Shigella, Streptococcus and Rumen cocci increased in the initial and recurrent groups, while the relative abundences of Praxobacter and Agarose decreased. Enterococcus, streptococcus, actinomyces, Rombuzia and Parasutterella were dominant groups in the recurrence group. Conclusion The diversity and abundance of intestinal flora decreased significantly in patients with recurrent intestinal polyps, and Enterococcus, actinomyces and Rombuzia were the dominant flora, which is of great significance for the prevention of recurrence of colorectal polyps.
Key words： Large intestine polyp; Intestinal flora; 16SrDNA sequencing method; Recurrent intestinal polyps; Bacteroidota
参考文献 References
[1] Ladabaum U, Dominitz J A, Kahi C, et al. Strategies for colorectal cancer screening[J]. Gastroenterology, 2020, 158(2): 418-432.
[2] Zauber A G, Winawer S J, O'Brien M J, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths[J]. New England Journal of Medicine, 2012, 366(8): 687-696.
[3] Wang Q P, He X X, Xu T, et al. Polyp recurrence after colonoscopic polypectomy[J]. Chinese Medical Journal, 2020, 133(17): 2114-2115.
[4] Chaoui I, Demedts I, Roelandt P, et al. Endoscopic mucosal resection of colorectal polyps: results, adverse events and two-year outcome[J]. Acta Gastro-Enterologica Belgica, 2022, 85.
[5] Zhong X,Wang Y,Xu J,et al.Gut microbiota signatures in tissues of the colorectal polyp and normal colorectal mucosa, and faeces[J].Frontiers in cellular and infection microbiology, 2023,12:1054808.
[6] Zhang X,Jin WW,Wang HG. Correlation between the neuroendocrine axis, microbial species, inflammatory response, and gastrointestinal symptoms in irritable bowel syndrome[J].World Journal of Gastroenterology,2024,30(35): 3985-3995.
[7] Guo X,Okpara ES,Hu W,et al.Interactive relationships between intestinal Flora and Bile acids[J].International Journal of Molecular Sciences,2022,23(15):8343.
[8] Stoian M, Becheanu G, Balescu I, et al. Recurrence and Carcinogenetic Rates of Colorectal Polyps[J]. Chirurgia (Bucharest, Romania: 1990), 2024, 119(1): 21-35.
[9] Hale VL,Chen J,Johnson S,et al.Shifts in the fecal microbiota associated with adenomatous polyps[J].Cancer Epidemiology, Biomarkers & Prevention,2017,26(1):85-94.
[10] Zeng X,Jia H,Zhang X,et al.Supplementation of kefir ameliorates azoxymethane/dextran sulfate sodium induced colorectal cancer by modulating the gut microbiota[J].Food & Function,2021,12(22):11641-11655.
[11] Senthakumaran T,Moen AEF,Tannæs TM,et al.Microbial dynamics with CRC progression: a study of the mucosal microbiota at multiple sites in cancers, adenomatous polyps, and healthy controls[J]. European Journal of Clinical Microbiology & Infectious Diseases,2023,42(3):305-322.
[12] Gao Y,Xu P,Sun D,et al. Faecalibacterium prausnitzii abrogates intestinal toxicity and promotes tumor immunity to increase the efficacy of dual CTLA4 and PD-1 checkpoint blockade[J]. Cancer Research,2023,83(22):3710-3725.
[13] Martini G,Ciardiello D,Dallio M,et al.Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab[J]. International Journal of Cancer,2022,151(3):473-480.
[14] Hertz S,Anderson JM,Nielsen HL,et al.Fecal microbiota is associated with extraintestinal manifestations in inflammatory bowel disease[J].Annals of Medicine,2024,56(1):2338244.
[15] Oh TJ,Sul WJ,Oh HN,et al.Butyrate attenuated fat gain through gut microbiota modulation in db/db mice following dapagliflozin treatment[J]. Scientific Reports,2019,9(1): 20300.
[16] Liu G,Tang J,Zhou J,et al.Short-chain fatty acids play a positive role in colorectal cancer[J].Discover Oncology, 2024,15(1):425.
[17] Pop OL,Vodnar DC,Diaconeasa Z,et al.An overview of gut microbiota and colon diseases with a focus on adenomatous colon polyps[J]. International journal of molecular sciences, 2020, 21(19):7359.